Kymera Investor Presentation Deck
KYMERA
Recognized leader in Targeted
Protein Degradation (TPD)
Building a fully-integrated,
global biotech company
Focusing on I/I and Oncology,
with disease-agnostic potential
Accelerating forward
integration through key
strategic partnerships
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
●
Overview
Focused on unlocking high value, undrugged targets using TPD
Advanced four programs to clinical stage to date, first degrader
program in I/I with IRAK4 demonstrating degrader differentiation
Demonstrated fidelity of translation of PK, PD and safety across
four clinical programs in both immunology and oncology
Demonstrated clinical activity in three programs in immunology
and oncology
Initiated two Phase 2 trials for KT-474/SAR444656, in potential
blockbuster indications (HS & AD) with Sanofi
Highly productive discovery engine delivering multiple INDs/year
with expanding focus in I/I
Well-capitalized with $435m of cash, enabling expansion of
clinical impact into areas with large clinical and commercial
opportunities
PAGE 3View entire presentation